Free base crystals

1. A crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (Compound A) as shown by the following chemical formula:

2. The crystal according to claim 1 , wherein the crystal is in non-solvate form.

3. The crystal according to claim 1 , wherein the crystal is in solvate form with alcohol.

4. The crystal according to claim 3 , wherein the crystal is in solvate form with methanol, ethanol, propanol or butanol.

5. The crystal according to claim 3 , wherein the crystal solvate form is mono-methanol, mono-ethanol, mono-n-propanol, mono-2-propanol or, mono-n-butanol.

6. The crystal according to claim 2 , wherein the crystal is in non-hydrate or hydrate form.

7. The crystal according to claim 1 , wherein said crystal exhibits an X-ray powder diffraction pattern selected from the following:

a) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 14.34, 11.65, 10.83, 7.91, 7.16, 6.89, 6.59, 5.82, 5.37, 5.03, 4.87, 4.64, 4.48, 4.23, 4.06, 3.93, 3.85, 3.75, 3.59, 3.45, 3.35, 3.21, 3.14, 3.01, 2.89, 2.81, 2.74, 2.68, 2.61, 2.47, 2.42, 2.34 and 2.28 Å;

b) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 14.67, 11.68, 10.96, 7.95, 7.39, 7.30, 6.80, 5.85, 5.57, 5.42, 4.86, 4.60, 4.36, 4.23, 4.14, 4.03, 3.95, 3.82, 3.71, 3.51, 3.46, 3.34, 3.22, 3.10, 3.02, 2.94, 2.91, 2.86, 2.77, 2.62, 2.55, 2.51, 2.42 and 2.33 Å;

c) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 14.67, 11.53, 10.80, 7.95, 7.25, 6.93, 6.59, 5.95, 5.76, 5.41, 4.86, 4.68, 4.47, 4.33, 4.24, 4.06, 3.95, 3.82, 3.61, 3.44, 3.36, 3.25, 3.19, 3.02, 2.96, 2.87, 2.77, 2.71, 2.63, 2.58, 2.53, 2.48, 2.38, 2.35 and 2.32 Å;

d) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 19.11, 12.51, 11.41, 11.01, 9.58, 8.95, 8.40, 6.60, 6.37, 6.10, 5.74, 5.33, 5.13, 4.83, 4.56, 4.39, 4.16, 3.91, 3.81, 3.58, 3.37, 3.26, 3.15, 3.03, 2.97, 2.87 and 2.84 Å;

e) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 12.58, 10.75, 8.89, 7.76, 7.36, 6.95, 6.57, 6.10, 5.50, 5.16, 4.74, 4.47, 4.12, 3.96, 3.87, 3.80, 3.72, 3.63, 3.47, 3.33, 3.25, 3.14, 3.06, 2.99, 2.91, 2.86, 2.81, 2.78, 2.61, 2.56, 2.47 and 2.33 Å; and

f) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 12.51, 10.80, 8.95, 7.78, 7.28, 6.93, 6.62, 6.14, 5.53, 5.13, 4.77, 4.45, 4.14, 3.96, 3.79, 3.64, 3.52, 3.40, 3.28, 3.15, 3.05, 2.65, 2.63, 2.51 and 2.47 Å.

8. The crystal according to claim 1 , wherein said crystal exhibits an X-ray powder diffraction pattern selected from the following:

a) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 14.34, 11.65, 10.83, 5.82, 4.87, 4.64, 4.48, 4.23, 3.93 and 3.21 Å;

b) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 14.67, 11.68, 10.96, 5.85, 4.86, 4.60, 4.23, 4.03, 3.95 and 3.22 Å;

c) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 14.67, 11.53, 10.80, 5.76, 4.86, 4.68, 4.47, 4.24, 4.06 and 3.95 Å;

d) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 12.51, 11.41, 11.01, 9.58, 8.95, 6.60, 5.13, 4.16 and 3.81 Å;

e) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 12.58, 10.75, 5.50, 4.74, 4.47, 3.96, 3.87, 3.80, 3.72 and 3.14 Å; and

f) an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of 12.51, 10.80, 5.53, 4.77, 4.45, 4.14, 3.96, 3.79, 3.64, 3.40, 3.28 and 3.15 Å.

9. The crystal according to claim 1 , wherein said crystal exhibits a Differential Scanning calorimetry (DSC) melting endotherm pattern as follows:

a) a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 107° C.-108° C.;

b) a Differential Scanning calorimetry (DSC) pattern comprising anendothermic peak between the range of 112−118° C.;

c) a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 97° C.;

d) a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 126° C.;

e) a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 84°-85° C.;

f) a Differential Scanning calorimetry (DSC) pattern comprising an endothermic at about 79° C., for example about 78.6° C.

10. A process for the preparation of a salt of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]-pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound A), comprising:

(1) dissolving a crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (Compound A) according to claim 1 in a non-solvate or solvate form in a solvent;

(2) adding an acid optionally in a solvent, to the solution obtained in the step (1), and

(3) stirring the mixture obtained in the step (2) to result in the objective salt.

11. The process according to claim 10 , wherein said salt is a salt crystal.

12. The process according to claim 10 , wherein said salt crystal is selected from fumarate, phosphate, (1-hydrox-2)-naphthoate, mesylate or benzoate salt crystal.

13. The process according to claim 11 , wherein the acid of step (2) is selected from fumaric acid, phosphoric acid, tartaric acid, methanesulfonic acid and benzoic acid.

14. The process according to claim 10 , wherein the solvent of step (1) and/or (2) is methanol, acetonitrile, acetone or mixtures thereof.

15. A process for the preparation of a mono-phosphate salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamine)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]-pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound A), which comprises:

(1) dissolving a crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (Compound A) according to claim 1 in a non-solvate or solvate form, in a solvent;

(2) adding phosphoric acid in a solvent to the solution obtained in the step (1), and

(3) stirring the mixture obtained in the step (2) to result in the objective mono-phosphate salt crystal.

16. The process according to claim 15 , wherein the solvent in the step (1) is selected from acetone and acetonitrile.

17. The process according to claim 15 , wherein the solvent in the step (2) is selected from acetone or acetonitrile.

18. The process according to claim 15 , wherein the amount of phosphoric acid to be added in the step (2) is almost (about) equimolecular quantity to the amount of crystal of the (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (Compound A) in non-solvate form or in solvate form of the step (1).

19. The process according to claim 15 , wherein water is additionally added in the step (2).

20. The process according to claim 15 , wherein the mixture is stirred at 20 to 70° C. in the step (3).

21. The process according to claim 20 , wherein the mixture is stirred at 50° C., 32° C., 38° C. or 39° C.

22. A salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound A) in hemi-fumarate, 0.5 ethyl acetate, 0.3 acetone solvate form; or in benzoate non-solvate form.

23. The salt crystal according to claim 22 , wherein the salt crystal is in hemi-fumarate, 0.5 ethyl acetate, 0.3 acetone solvate form, and exhibit an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of: 14.67, 11.97, 10.99, 8.19, 7.41, 6.98, 6.46, 6.14, 5.89, 5.59, 5.20, 5.01, 4.66, 4.61, 4.30, 4.07, 3.93, 3.74, 3.59, 3.47, 3.34, 3.23, 3.06, 3.00, 2.94, 2.86, 2.80, 2.62, 2.54, 2.51 and 2.40 Å.

24. The salt crystal according to claim 22 , wherein the salt crystal is in hemi-fumarate, 0.5 ethyl acetate, 0.3 acetone solvate form, and exhibit an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of: 14.67, 11.97, 7.41, 6.98, 6.46, 5.20, 5.01, 4.66, 4.30, 4.07, 3.93, 3.74 and 3.59 Å.

25. The salt crystal according to claim 22 , wherein the salt crystal is in benzoate non-solvate form, and exhibits an X-ray powder diffraction pattern comprising at least five peaks having d-spacing values selected from the group consisting of: 14.15, 12.17, 7.31, 5.93, 5.59, 5.15, 4.52, 4.07, 3.92, 3.64, 3.50, 3.42, 3.29, 3.21 and 3.11 Å.

26. The salt crystal according to claim 22 , wherein the salt crystal is in benzoate non-solvate form, and exhibits an X-ray powder diffraction pattern comprising peaks having d-spacing values selected from the group consisting of: 14.15, 7.31, 5.15, 4.07 and 3.92, 3 Å.

27. A process for the preparation of the crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent-[4,5]imidazo[1,2-a]-pyrazolo[4,3-e]pyrimidin-4(2H)-one free base according to claim 1 (compound A) in solvate form, comprising:

(1) dissolving a salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]-pyrimidin-4(2H)-one (compound A) in a non-solvate or solvate form, in the mixture of an organic solvent and aqueous basic solution,

(2) separating the organic layer,

(3) adding a solvent to the organic solution obtained in the step (2), and

(4) stirring the mixture obtained in the step (3) to result in the objective crystal.

28. The process according to claim 27 , wherein the crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent-[4,5]imidazo[1,2-a]-pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (Compound A) being prepared is in an ethanol solvate form; the salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]-pyrimidin-4(2H)-one (compound A) of step (1) is a hemi-fumarate salt crystal, in a non-solvate or solvate form; and the solvent of step (3) is ethanol.

29. The process according to claim 28 , wherein the salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]-pyrimidin-4(2H)-one (compound A) hemi-fumarate in a non-solvate or solvate form of step (1) is the salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one hemi-fumarate, 0.5 ethyl acetate, 0.3 acetone solvate.

30. The process according to claim 27 , wherein the crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamine)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]-pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (compound A) in ethanol solvate form is a crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]-pyrazolo[4,3-e]pyrimidin-4(2H)-one free base (compound A) mono-ethanol solvate.

31. The process according to claim 15 , further comprises the steps of preparing the free base crystal of Compound A.

32. A process for the preparation of a mono-phosphate salt crystal of Compound A comprising:

(a) dissolving the salt crystal of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]-pyrimidin-4(2H)-one (compound A) in hemi-fumarate in a non-solvate or solvate form, in the mixture of an organic solvent and aqueous basic solution;

(b) separating the organic layer;

(c) adding ethanol, to the organic solution obtained in the step (b);

(d) stirring the mixture obtained in the step (c) to result in the objective crystal;

(e) isolating the crystals obtained form step (d);

(f) dissolving the crystals obtained from step (e);

(g) adding phosphoric acid in a solvent to the solution obtained in step (b); and

(h) stirring the mixture obtained in step (c) to result in the objective salt.